Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 12-18% of all BCs.Breast cancer (breast cancer) is the most common oncological disease in women in the Uzbekistan. Data from epidemiological studies show that TNBC is more common in young women (up to 50 years) before menopause. In addition, the likelihood of TNBC is higher in women with early menarche, the first pregnancy at an earlier age, a short period of breastfeeding, and an increased body mass index. It should be not that the prognosis for TNBC does not depend on the degree of differentiation of the tumor, the presence of lymph node metastases, the size of the tumor or the treatment performed. The aggressiveness of TNBC was also confirmed by the maximum risk of recurrence during the first three years after surgical treatment with a maximum mortality within the first 5 years. TNBC is a subtype of tumors with a special character of metastasis. Based on the above, we have undertaken the present work, having set ourselves the following goal: to improve immediate and long-term results of treatment of patients with locally advanced thyroid cancer by using the most effective diagnostic methods and comprehensive treatment.
INTRODUCTION
Triple-negative breast cancers have a relapse pattern that is very different from hormone-positive breast cancers: the risk of relapse is much higher for the first 3-5 years but drops sharply and substantially below after those hormone-positive breast cancers. In this review, data on the use of gemsitabini in metastatic triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). The available data show the clinical potential of based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor.In 2016, 1,380,000 new cases and 458,000 deaths for BC were reported worldwide, of which there were 332,000 new cases and 79,000 deaths in Asia 1, 4 .
BC in the territory of the Republic among urban and rural population by determining the average annual intensive and standardized incidence rates for the years 2008-2010. The highest standardized incidence rates registered in Tashkent city (22,5%x>00), Navaiy (12,4%00), Bukhara (11,1%00) and Tashkent regions (11,0%00) and lowest in Surkhandarya (6,3%00) and Kashkadarya (7,5%00) . On the territory of the Republic those in urban areas more often suffer from cancer of the breast (13,2%x>00) than rural (8,5%00) 2, 3 .
The highest incidence was within the age intervals 50-59 -18,0%00, 60-69 -31,2%00, 70 years and older -19,3%00. In the structure of mortality of the female Despite the improvement of the methods of diagnosing this pathology, more than 50% of primary patients annually turn to the oncologist in the III and IV stages of the disease.
Purpose of the study is to evaluate the effectiveness of various chemotherapy regimens for neoadjuvant, adjuvant and palliative polychemotherapy (metastatic) in patients triple negative breast cancer with improved long-term treatment outcomes.
MATERIALS AND METHODS
The object of our study will be patients with breast cancer with a triple negative phenotype. In total, retrospective and prospective groups of patients treated in 2012-2017 will be studied. in Tashkent City oncology in the department of oncology and chemotherapy (n = 99), patients with triple negative breast cancer. Thus, the patients included in the study were characterized by a set of unfavorable signs: in 93% of cases the tumors were characterized by high Ki-67, in 53%-87.7% of casesby II-IV grade of malignancy. Criteria for selecting patients: Progression of breast cancer was detected in the period from 12 to 60 months after the operative removal of the primary tumor (metachronous metastases); ECOG 0-1. The age of patients older than 18 years. The presence of the result of immunohistochemical analysis of the primary tumor, and in the experimental group a comparative analysis of the primary tumor and distant metastases. Functional status according to ECOG (FS) was from 0 to 2. All patients had measurable normal kidney and liver function, satisfactory parameters of general and biochemical blood tests (leukocytes> 4.5 x 109 / L, neutrophily> 2.0 x 109 / L, hemoglobin> 9 g / dL, blood transfusions were not tolerated for the last two weeks, platelets> 100 x 109 / L, creatinine <130 μmol / L, total bilirubin <1.5 of the upper limit of normal (CGI), ALT and ACT <1.5 VGN.After randomization, patients in a 2: 1 ratio were included in two treatment groups: 1) chemotherapy with doxorbicin, and/or 2) chemotherapy with platinum drugs. As chemotherapy, the following options were used: taxanes (docetaxel or paclitaxel), platinum, anthracyclines, gemcitabine, doxorubicin, cyclophosphani, capecitabine.
RESULTS

The triple-negative BCs (TNBCs)
The most important biological markers, not only for classification of BC but also for, the therapeutic strategy are the hormonal receptors (estrogen [ER] and progesterone [PgR] receptor) and the HER2 receptor status 5 . Tumors that are ER-, PgR-, and HER2-negative are known as TNBC and account for about 12-20% of BCs 4 . These tumors develop earlier in life, especially in premenopausal women, and have a poorer prognosis than the other types of BC due to the higher aggressiveness. These factors may be a major reason for the high-risk relapse, and shorter progression-free survival (PFS) and overall survival (OS) reported for this disease [3] [4] [5] [6] . The main general characteristics of TNBC are summarized in Table 1 . 
The treatment of TNBCs
A proportion of TNBC is highly sensitive to chemotherapy but with a short PFS and a lower OS 15 . Current therapeutic strategies include chemotherapeutic drugs (anthracyclines, taxanes, platinum derivatives, and gemsitabine) and biological drug 11, 16 . The efficacy of anthracyclines and gemsitabine in metastatic BC is higher in ER-negative tumors; for this reason, both classes are indicated as first-line treatment of TNBC, even if with a short-lasting benefit 14 . Another group of drugs with proven activity in TNBC are the platinum derivatives cisplatin and carboplatin [13] [14] [15] [16] .
Guidelines for the treatment of TNBCs
There are no specific guidelines for the management of TNBC: the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and AssociazioneItaliana di OncologiaMedica (AIOM) Guidelines recommend that TNBC be treated with chemotherapy (monotherapy or combination therapy) but do not specify the most appropriate drugs.
Taxanes and their combinations recommended by NCCN, ESMO, and AIOM guidelines for triplenegative BC The ESMO Guidelines states that cytotoxic chemotherapy is the standard of care for the treatment of TNBC and that the choice of the regimen should be made after consideration of disease-related factors (disease-free survival [DFS], previous therapies and response, tumor burden, and need for rapid disease/symptom control) and patient-related factors (patient preferences, biological age, menopausal status, comorbidities and performance status, and socioeconomic and psychological factors). Combination chemotherapy is more often required because of frequent visceral involvement, aggressive course, and risk of rapid patient deterioration. Finally, there is no a standard approach for chemotherapy after first line 16, 17 .
The role of taxanes in TNBC
The role of taxanes in TNBC is well established after the many studies evaluating the efficacy of taxane-based regimens in neoadjuvant, adjuvant, and metastatic disease settings. Neoadjuvant therapy has been used for a long time for reducing the size and the extension of locally advanced tumors, but now it is extensively used also in early BC not suitable for primary conservative surgery, with an added predictive value for the longterm outcome of the disease. Actually the best efficacy target for neoadjuvant therapy is expressed as pathological complete response (pCR). The predictive value of pCR as a surrogate for long-term clinical benefit has been recently confirmed by the retrospective pooled analysis of Cortazar et al 18 . This meta-analysis was based on the pCR, overall response rate (ORR), and event-free survival (EFS) data of 12 international clinical trials on a total 11,550 patients. The analysis compared the three main definitions of pCR in order to establish their association with long-term efficacy: ypT0 ypN0 (no invasive and in situ tumor in the breast and auxiliary lymph nodes); ypT0/is ypN0 (no invasive tumor in the breast and axiliary lymph nodes, independent of the presence of in situ ductal carcinoma); and ypT0/is ypN0/is (no invasive tumor in the breast, independent of the presence of in situ ductal carcinoma or lymph nodes involvement). The better combination between pCR and long-term effect was observed in patients with an aggressive tumor (TNBC; high-grade; ER/PgR-positive, HER2-negative; HER2-positive; and ER-and PgR-negative) 19 .
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Several studies on neoadjuvant therapy confirmed the sensitivity of TNBC to cytotoxic drugs, as well as the importance of platinium-based chemotherapy. Rouzier et al evaluated the molecular-based chemosensitivity patients treated with carboplatin and taxanes neoadjuvant therapy, and a pCR was observed in 45% of BL tumors and in 6% of luminal tumors (A and B) . [20] [21] .
The study evaluated in 53 women randomized to neoadjuvant doxorubicin and docetaxel for four cycles or doxorubicin and cyclophosphamide (AC) for four cycles followed by docetaxel for four cycles. The overall was 10.6% (7% with the two-drug regimen and 14.3% with the triplet one). The efficacy of taxanebased neoadjuvant therapy was further confirmed by more recent trials. Wu et al evaluated the efficacy of neoadjuvant therapy with docetaxel plus epirubicin, and the OS in 64 patients with TNBC and in 65 patients with non-TNBC. A pCR was observed in 25.9% of TNBCs, significantly higher than in the other subtypes (P=0.019) 24 .
The New England Journal of Medicine published a report by Bear et al of another trial of neoadjuvant chemotherapy with or without carboplatini. This Phase III randomized trial assigned 46 patients with HER2negative BC to receive docetaxel (100 mg/m 2 every 21 days) or docetaxel (75 mg/m 2 day 1) plus capecitabine (825 mg/m 2 twice a day days 1 to 14) or docetaxel (75 mg/m 2 day 1) plus gemcitabine (1,000 mg/m 2 days 1 and 8) for four cycles. All regimens were followed by AC for a further four cycles. All patients were also randomized to receive carboplatini (AUC=5) or not for the first six cycles of chemotherapy. Results showed first of all that the addition of carboplatiniand gemcitabine did not improve the rate ofdocetaxel alone and showed increased toxicity and that the toxicity of carboplatini was manageable and as expected from previous trials and, significantly increased the overall pCR rate (34.5% vs 28.2%) (P=0.02). The multiple logistic regression model showed that TNBC subtype, high grade, and smaller tumor size were associated with higher rates in the breast, but when considering the breast and nodes, the addition of carboplatiniwas significantly related to a better result in hormone receptor-positive tumors only.
In the randomized 45 patients with TNBC were treated with weekly paclitaxel plus liposomal doxorubicin (once a week for 18 weeks) every 3 weeks and were randomized to receive weekly carboplatin (area under the time-concentration curve [AUC] =2) or not. The pCR (ypT0ypN0) rate was 16% higher with the addition of carboplatin (53.2% vs 36.9%) (P=0.005). The toxicity was also significantly higher, with 53% discontinuation (41% with AUC reduced to 1.5). Data on the BRCA mutation are not yet available in order to assess the correct role of carboplatin 18, 19 .
The adjuvant setting
Studies in adjuvant setting also confirmed the activity and relevance of taxanes in TNBCs. Hayes et al retrospectively analyzed the histological samples of 52 patients enrolled in the study in order to evaluate the role of HER2 status on clinical end points. Patients were divided in four groups: endocrine receptor-and HER2negative (TNBC); endocrine receptor-and HER2positive; endocrine receptor-positive and HER2negative; endocrine receptor-negative and HER2positive. Adding taxanes/cyclophosphani withanthracycline improved DFS both in HER2-positive patients, independently from endocrine receptor status, and in TNBC patients. No clinical benefit was observed in HER2-negative and endocrine receptor-positive tumors. This explorative analysis suggests that paclitaxel added to the adjuvant regimen significantly improves the outcome in TNBCs 20, 21, 22 .
The study of conducted on 52 patients, evaluated in the adjuvant setting the efficacy of AC followed by weekly or 3-weekly (q3w) docetaxel or paclitaxel. The results showed an improvement both in DFS and 5-year OS with weekly paclitaxel with respect to q3w paclitaxel. In TNBCs, the benefit of conventional weekly paclitaxel in term of DFS was 37% higher than the q3w regimen 23, 24, 26 .
The metastatic setting
Conventional gemsitabine have a central role in the treatment of metastatic BC, based on several evidences of their benefits on clinical outcomes, such as OS, time to progression (TTP) 25, 26 .
Even if conventional gemsitabine demonstrated to be more active in endocrine receptor-negative tumors and are indicated in the first-line treatment of TNBC (although a specific benefit in this setting was not observed), it should be considered that they are commonly used in adjuvant therapy and cannot be rechallenged in case of short disease-free interval (<12 months).
Fan et al evaluated the efficacy of gemsitabine combined with cisplatin or capecitabinewith docetaxelin the first-line treatment of patients with metastatic TNBC 27 . The ORR was significantly higher in patients treated with gemsitabine plus cisplatin than with docetaxel plus capecitabine (63% vs 15.4%) (P=0.001), as were the median PFS (10.9 vs 4.8 months) (P<0.001) and median OS (32.8 vs 21.5 months) (P=0.027), confirming the role of platinum in TNBC 29 .
The TNBC trial was based on the hypothesis that because BRCA1/2germline mutations produce BCs that have defects in homologous recombination DNA repair, carboplatin would be lethal to cells with germline and somatic mutations in BRCA1/2. In other words, carboplatin might be an especially good therapy in terms of exploiting the defect in homologous recombination DNA repair, and this is why patients with BRCA1/2 mutations were included with TNBC patients. The results showed no significant difference in response rates between carboplatin and gemsitabini in the overall patient group or in patients who received either agent as first-line therapy and then crossed over to the other agent as second-line treatment 28, 30 .
In conclusion, the main reason of failure in metastatic BC is resistance to the standard drugs, which can be intrinsic or acquired. Patients with disease progression or resistance could not have a cross-resistance with other ISSN: 2250-1177
[167] CODEN (USA): JDDTAO drugs, such as capecitabine, gemcitabine, which demonstrated their efficacy in patients with advanced BC pretreated with carboplatini with gemsitabin.
CONCLUSION
TNBC is characterized by the absence of ER-, PgR-, and HER2-negativity: for this reason the only therapeutic option is chemotherapy. Even if these tumors are chemosensitive, as showed by the high pCR obtained with neoadjuvant therapy, metastatic patients have a short PFS; this the chemosensitivity does not translate in an improvement of PFS or OS, and the overall prognosis for these tumors is poor.The studies performed taxanes with platinium based chemotherapy demonstrated their efficacy in the treatment of TNBC in by setting neoadjuvant, and cyclophosphan with doxorubisin or doxetaxel more effectively in adjuvant regimens, gemsitabines with platinium was detected more metastatic triple negative breast cancer, international and national guidelines recommend the as possible active first-line therapeutic options for TNBC.
